Future Uses for CGM: Insights from Dexcom's CEO
Decision brief
Answer first · skim in under a minute
Dexcom's CEO hints at innovative future uses for continuous glucose monitoring (CGM) technology. This article explores the implications for the pharmaceutical sector.
Key questions this brief answers
- What is Dexcom Stelo and when did it receive FDA clearance?
- How could CGM technology be used in clinical trials?
- What is the global prevalence of diabetes driving CGM demand?
- What are the key differences between Dexcom G7 and Stelo?
Dexcom CEO Kevin Sayer is positioning continuous glucose monitoring (CGM) technology to expand far beyond diabetes management into preventive healthcare, clinical trials, and metabolic wellness applications. The company's FDA-cleared Stelo system became the first over-the-counter CGM for non-insulin users in March 2024, opening a market potentially larger than the traditional diabetes segment.
Contents10 sections
Key Takeaways
- The FDA cleared Dexcom Stelo as the first OTC CGM for non-insulin users on March 5, 2024 (510(k) K234070), enabling access without prescription for adults 18 and older.
- CEO Kevin Sayer has outlined plans to expand CGM applications into clinical trials, personalized medicine, and metabolic health monitoring for the broader population.
- The International Diabetes Federation estimates 589 million adults globally had diabetes in 2024, with projections reaching 853 million by 2050, driving sustained CGM demand.
- Stelo features a 15-day wearable sensor paired with a smartphone app, delivering glucose readings every 15 minutes for lifestyle insights rather than intensive insulin dosing.
- Pharmaceutical companies are exploring CGM integration for real-time drug response monitoring and adaptive dosing protocols in clinical development.
What Is Dexcom's Vision for CGM Beyond Diabetes?
Kevin Sayer has outlined a strategy to extend continuous glucose monitoring (CGM) beyond traditional diabetes care. The company wants to make glucose sensing available to anyone who wants to understand how diet, exercise, sleep, and stress affect their health.
This move targets non-insulin users who may benefit from glucose data for preventive health. The metabolic health market is a big opportunity. It could grow larger than the market for insulin-dependent diabetes patients. Dexcom is positioning the technology as a wellness tool, not just a medical device for chronic disease.
When Did the FDA Clear Dexcom Stelo for OTC Use?
The U.S. Food and Drug Administration granted 510(k) clearance to Dexcom Stelo on March 5, 2024. This was the first over-the-counter continuous glucose monitor approved for non-insulin users. It includes people without diabetes who want to track glucose for general health.
The clearance (K234070) classified Stelo as an "Integrated Continuous Glucose Monitor for Non-Intensive Glucose Monitoring, Over-The-Counter." The FDA found the device was similar to products already on the market. Clinical studies showed performance like other CGM systems. Side effects were limited to minor skin irritation, infection, and discomfort at the sensor site.
Users must remove the device before MRI, CT scans, or diathermy treatments. It may show errors in people taking hydroxyurea or on dialysis. The sensor goes only on the back of the upper arm.
How Does Stelo Differ from Dexcom G7?
While both devices use the same core biosensing technology, Stelo and G7 serve different patient populations and use cases. Understanding these distinctions is critical for healthcare providers and pharmaceutical teams evaluating CGM partnerships.
| Feature | Dexcom Stelo | Dexcom G7 |
|---|---|---|
| Indication | Non-intensive glucose monitoring | Diabetes management |
| Availability | Over-the-counter (OTC) | Prescription only |
| Age Range | Adults 18+ | Ages 2 and up |
| Sensor Duration | 15 days | 10 days |
| Primary Use | Lifestyle and metabolic insights | Insulin dosing decisions |
| FDA Clearance | K234070 (March 2024) | K213919 (December 2022) |
What Are the Pharmaceutical Industry Implications?
CGM expansion into non-diabetic groups creates opportunities for drug companies. Developers can use continuous glucose monitoring in clinical trials to capture real-time metabolic data. This may shorten trial timelines and improve safety tracking.
Metabolic health plays a role in conditions from heart disease to brain disorders. CGM data could enable dosing changes based on individual glucose patterns. This approach fits the industry's move toward precision medicine.
Partnerships between drug companies and CGM makers like Dexcom could speed up innovation. Combination therapies that pair glucose sensors with drug delivery systems are a growing area. Read our analysis of AI gaps in CDMO capacity planning.
How Large Is the Addressable Market?
The global diabetes prevalence figures underscore the scale of opportunity for CGM manufacturers and their pharmaceutical partners. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20-79 were living with diabetes worldwide in 2024. This figure is projected to reach 853 million by 2050.
Over 81% of adults with diabetes live in low- and middle-income countries, where access to advanced monitoring technologies remains limited. However, the Stelo OTC clearance opens pathways to reach the broader population of non-diabetic individuals interested in metabolic health—a market segment that could eventually exceed the traditional diabetes market.
The blood glucose monitoring market is valued at over $6.4 billion globally. CGM devices are the fastest-growing segment as costs drop and coverage expands. See our diabetes drug pipeline analysis.
What Are the Clinical Trial Applications?
CGM use in clinical trials gives researchers continuous metabolic data rather than spot glucose checks. This helps for drugs that affect metabolism, including those for diabetes, obesity, heart disease, and some cancer therapies.
Key trial applications include:
- Real-time safety monitoring: Immediate detection of hypoglycemic or hyperglycemic events during dosing studies
- Pharmacokinetic correlation: Understanding how drug absorption and metabolism affect glucose levels over time
- Patient stratification: Identifying responders vs. non-responders based on metabolic profiles
- Endpoint enrichment: Adding continuous glucose metrics as secondary or exploratory endpoints
The 15-day Stelo sensor fits well with typical Phase I dosing periods. The G7 system's 10-day wear time suits longer Phase II/III studies. See our clinical trial digitization trends.
What Regulatory Pathways Has Dexcom Navigated?
Dexcom's regulatory strategy shows how CGM classification has evolved at the FDA. The G7 system got initial 510(k) clearance in December 2022 (K213919). Later clearances expanded its uses and interoperability. These approvals paved the way for Stelo's OTC classification.
The difference between prescription and OTC CGM depends on intended use and risk. Prescription CGMs like G7 support insulin dosing decisions and need doctor oversight. Stelo's OTC clearance required showing its software and labeling guide non-insulin users not to make medication decisions based on device readings alone.
Frequently Asked Questions
What is Dexcom Stelo and when did it receive FDA clearance?
Dexcom Stelo is the first over-the-counter (OTC) continuous glucose monitoring (CGM) system cleared by the FDA for non-insulin users, including non-diabetic individuals. The FDA granted 510(k) clearance (K234070) on March 5, 2024. The system provides glucose readings every 15 minutes via a wearable sensor and smartphone app.
How could CGM technology be used in clinical trials?
CGM technology enables real-time glucose monitoring in clinical trials, allowing researchers to track metabolic responses to investigational drugs continuously. This provides richer datasets than traditional fingerstick measurements, potentially accelerating drug development timelines and enabling personalized dosing strategies based on individual metabolic profiles.
What is the global prevalence of diabetes driving CGM demand?
According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20-79 were living with diabetes globally in 2024. This number is projected to rise to 853 million by 2050. The growing prevalence, combined with expanding indications for CGM use beyond insulin-dependent patients, is driving significant market expansion.
What are the key differences between Dexcom G7 and Stelo?
Dexcom G7 is an integrated CGM system indicated for diabetes management, approved for ages 2 and up, and requires a prescription. Stelo is the OTC version designed for non-insulin users aged 18 and older, featuring a 15-day sensor and tailored software for lifestyle and metabolic health insights rather than intensive insulin dosing decisions.
Primary Sources
- U.S. Food and Drug Administration. "510(k) Summary: Dexcom Stelo Glucose Biosensor System (K234070)." March 5, 2024. accessdata.fda.gov
- U.S. Food and Drug Administration. "510(k) Summary: Dexcom G7 Continuous Glucose Monitoring System (K213919)." December 7, 2022. accessdata.fda.gov
- International Diabetes Federation (IDF). "IDF Diabetes Atlas (10th Edition)." 2024. diabetesatlas.org
- Dexcom, Inc. "Dexcom Reports Fourth Quarter and Full Year 2023 Financial Results." Investor Relations. February 2024. investors.dexcom.com
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for CGM.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
